Latest KFF Health News Stories
Many Doctors Treating Alcohol Problems Overlook Successful Drugs
Two prescription medications have been found to be successful in helping many patients with alcohol cravings. Yet they are rarely used and many patients don’t know they exist.
Young Boy’s Struggle To Survive Sparked Push For Drugs For Terminally Ill
Ten-year-old Josh Hardy died last month. His struggle to survive helped to spur laws to get unapproved drugs to the terminally ill.
The Need To Replace EpiPens Regularly Adds To Concerns About Cost
The drug’s manufacturer says it has an expiration date of 12 to 18 months but that includes distribution time, so many customers find they have to buy a new device at least once a year.
Poll Finds Majority Of Americans Want Restraints On Drug Prices
As the spiraling costs attract headlines, many people are looking to the government to rein in prescription drug prices, according to the Kaiser Family Foundation poll.
Specialty Drug Costs Soar 30% For California Pension Fund
Such medications account for more than a quarter of the state agency’s $2.1 billion in pharmacy costs.
When Drug Reviewers Leave The FDA, They Often Work For Pharma
Researchers examine the Food and Drug Administration’s “revolving door” regarding employees who worked on cancer and hematology drugs.
It’s Not Just For Kids: Medicare EpiPen Spending Up 1,100 Percent
The number of prescriptions for Medicare beneficiaries is on the rise, too.
Veterans Courted In California’s Ballot Fight Over Curbing Drug Prices
The initiative would prohibit California state agencies from paying more for a prescription drug than what the Department of Veterans Affairs pays. Both sides are deploying veterans’ sympathetic and trusted image to win over voters.
FDA Approves First Drug To Treat Rare Form Of Muscular Dystrophy
The FDA, reacting to lobbying by patients and families, has approved a drug for Duchenne muscular dystrophy, a rare and lethal disease.
Candidates Decry High Drug Prices, But They Have Few Options For Voters
Drug prices rise for a variety of reasons but opportunities for the government to control them is limited.
Behind The EpiPen Monopoly: Lobbying Muscle, Flailing Competition, Tragic Deaths
A closer look shows that industry lobbying was just one factor in EpiPen’s sales explosion.
Study Says Concerns About Orphan Drug Spending Are Unjustified
A study in Health Affairs concludes that orphan drugs for rare diseases are not having a widespread or deep impact on health care spending.
EpiPen Controversy Fuels Concerns Over Generic Drug Approval Backlog
Four years after a huge push to speed generics to market, the FDA has more than 4,000 generics waiting for approval.
Mylan’s Generic EpiPen — A Price Break Or Marketing Maneuver?
As news that Mylan will make available a generic version of its own brand-name product, KHN answers key questions about how this development could affect consumers.
‘America’s Other Drug Problem’: Copious Prescriptions For Hospitalized Elderly
Older people are often given a huge number of medications, and many of them are unnecessary or even harmful.
Government-Protected ‘Monopolies’ Drive Drug Prices Higher, Study Says
Researchers at Harvard University examined thousands of studies to determine why drug prices have climbed and what might be done about it.
Insurance Rules Can Hamper Recovery From Opioid Addiction
Medicaid and other health insurers require doctors to file time-consuming paperwork before allowing them to prescribe drugs that help people quit opioids. That delay fosters relapse, specialists say.
Syncing Up Drug Refills: A Way To Get Patients To Take Their Medicine
A study published in Health Affairs concludes that the idea of coordinating prescription refill timelines for people with multiple chronic conditions could improve their medication adherence and health outcomes.
Teaching Future Doctors About Addiction
Most medical schools offer very little education on treating opioid addiction. Stanford University’s medical school is trying to ramp it up.
Study Bodes Well For Biosimilars But Highlights Need For More Research
Some experts said the findings stemming from this systematic review of existing studies was reassuring, but not surprising.
